HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma

Ann Oncol. 2017 Dec 1;28(12):3103-3104. doi: 10.1093/annonc/mdx502.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / adverse effects*
  • Antiviral Agents / administration & dosage
  • Hepatitis B virus / isolation & purification*
  • Hepatitis, Viral, Human / chemically induced*
  • Hepatitis, Viral, Human / drug therapy
  • Hepatitis, Viral, Human / immunology
  • Hepatitis, Viral, Human / virology
  • Humans
  • Ipilimumab / adverse effects*
  • Male
  • Melanoma / drug therapy*
  • Melanoma / immunology
  • Melanoma / virology
  • Middle Aged
  • Nivolumab
  • Tenofovir / administration & dosage

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological
  • Antiviral Agents
  • Ipilimumab
  • Nivolumab
  • Tenofovir